Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Abbvie Inc's Business Segments
Abbvie Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
19
Largest Segment
Immunology Skyrizi
Total Revenue
$ 15,002
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Immunology Skyrizi29.9%
- Immunology Rinvoq14.1%
- All other6.8%
- Neuroscience Botox Therapeutic6.7%
- Neuroscience Vraylar6%
- Oncology Venclexta5.1%
- Immunology Humira4.6%
- Aesthetics Botox Cosmetic4.5%
- Oncology Imbruvica3.7%
- Other Key Products Mavyret2.3%
- Neuroscience Ubrelvy2.3%
- Neuroscience Qulipta2%
- Aesthetics Other Aesthetics1.9%
- Other Key Products Linzess1.9%
- Aesthetics Juvederm Collection1.5%
- Neuroscience Vyalev1.3%
- Oncology Elahere1.3%
- Neuroscience Other Neuroscience0.8%
- Oncology Epkinly0.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Immunology Skyrizi | $ 4,483 | 29.9% |
| Immunology Rinvoq | $ 2,119 | 14.1% |
| All other | $ 1,025 | 6.8% |
16 more segments available
Sign in to unlock the full Abbvie Inc dataset.
Revenue by Product & Service Category - FY
- Skyrizi25.2%
- Rinvoq9.4%
- Other Products6.8%
- Vraylar6%
- Botox Therapeutic5.6%
- Botox Cosmetic2.5%
- Creon2.4%
- Venclexta2.3%
- Imbruvica2.2%
- Ubrelvy2.2%
- Linzess/Constella1.8%
- Other Aesthetics1.7%
- Mavyret1.2%
- Elahere1.1%
- Vyalev0.6%
- Juvederm Collection0.6%
- Other Neuroscience0.3%
- Epkinly0.2%
- Other Oncology0.2%
- H U M I R a0%
- Qulipta0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Skyrizi | $ 3,775 | 25.2% |
| Rinvoq | $ 1,405 | 9.4% |
| Other Products | $ 1,025 | 6.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
18 more categories available
Sign in to unlock the full Abbvie Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Immunology Skyrizi29.9%
- Immunology Rinvoq14.1%
- All other6.8%
- Neuroscience Botox Therapeutic6.7%
- Neuroscience Vraylar6%
- Oncology Venclexta5.1%
- Immunology Humira4.6%
- Aesthetics Botox Cosmetic4.5%
- Oncology Imbruvica3.7%
- Other Key Products Mavyret2.3%
- Neuroscience Ubrelvy2.3%
- Neuroscience Qulipta2%
- Aesthetics Other Aesthetics1.9%
- Other Key Products Linzess1.9%
- Aesthetics Juvederm Collection1.5%
- Neuroscience Vyalev1.3%
- Oncology Elahere1.3%
- Neuroscience Other Neuroscience0.8%
- Oncology Epkinly0.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Immunology Skyrizi | $ 4,483 | 29.9% |
| Immunology Rinvoq | $ 2,119 | 14.1% |
| All other | $ 1,025 | 6.8% |
16 more segments available
Sign in to unlock the full Abbvie Inc dataset.
Description of Abbvie Inc
AbbVie Inc. is a global, research-based biopharmaceutical company that focuses on the discovery and development of innovative therapies. The company operates primarily in the pharmaceutical sector, with a strong emphasis on several therapeutic areas, including immunology, oncology, neuroscience, virology, and womens health.
AbbVie is known for its diverse portfolio of medications, many of which address complex and serious diseases. Key products include Humira, a leading treatment for autoimmune diseases, and newer therapies such as Rinvoq and Skyrizi for inflammatory disorders.
The company invests heavily in research and development (R&D) to drive innovation and expand its product pipeline. Its R&D efforts are complemented by collaborations and partnerships with other biopharmaceutical companies, academic institutions, and research organizations to enhance its capabilities and accelerate the development of new therapies.
AbbVie also engages in commercial operations worldwide, with a focus on market access, commercialization strategies, and patient support programs to ensure that its therapies reach the patients who need them.
Corporate social responsibility is an integral part of AbbVie’s operations, with initiatives aimed at improving access to healthcare, promoting sustainability, and supporting communities through various outreach programs.
Overall, AbbVie combines scientific expertise with a commitment to addressing significant unmet medical needs, positioning itself as a leader in the biopharmaceutical industry.
AbbVie is known for its diverse portfolio of medications, many of which address complex and serious diseases. Key products include Humira, a leading treatment for autoimmune diseases, and newer therapies such as Rinvoq and Skyrizi for inflammatory disorders.
The company invests heavily in research and development (R&D) to drive innovation and expand its product pipeline. Its R&D efforts are complemented by collaborations and partnerships with other biopharmaceutical companies, academic institutions, and research organizations to enhance its capabilities and accelerate the development of new therapies.
AbbVie also engages in commercial operations worldwide, with a focus on market access, commercialization strategies, and patient support programs to ensure that its therapies reach the patients who need them.
Corporate social responsibility is an integral part of AbbVie’s operations, with initiatives aimed at improving access to healthcare, promoting sustainability, and supporting communities through various outreach programs.
Overall, AbbVie combines scientific expertise with a commitment to addressing significant unmet medical needs, positioning itself as a leader in the biopharmaceutical industry.
AbbVie Inc. is a prominent global biopharmaceutical company established in 2013 following its separation from Abbott Laboratories. The companys focus encompasses a wide array of therapeutic areas, with its primary segments being immunology, oncology, neuroscience, virology, and womens health. Below is an extensive overview of the segments, products, and services that AbbVie offers:
Pharmaceutical Products Segment
1. Immunology
AbbVies immunology portfolio is headlined by HUMIRA (adalimumab), one of the worlds top-selling drugs, which has received approval for a variety of autoimmune diseases. This includes conditions such as:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Hidradenitis Suppurativa
In addition to HUMIRA, AbbVie has introduced newer agents into the market, including:
- RINVOQ (upadacitinib): An oral Janus kinase (JAK) inhibitor that treats rheumatoid arthritis and atopic dermatitis, emphasizing its effectiveness in managing moderate to severe conditions.
- ABBV-181: An investigational drug under development specifically targeting atopic dermatitis and other inflammatory diseases, showcasing AbbVies commitment to innovation within this therapeutic area.
Oncology
AbbVie has positioned itself as a critical player in oncology, with a focus on developing therapies for various cancers. Key products include:
- IMBRUVICA (ibrutinib): A Brutons tyrosine kinase (BTK) inhibitor that has gained approval for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), offering significant benefits in terms of progression-free survival.
- VENCLEXTA (venetoclax): An oral BCL-2 inhibitor, which is often utilized in combinations for treating CLL, further enhancing treatment efficacy.
- ABBV-927: Currently in clinical trials for various cancer types, this drug is indicative of AbbVies ongoing commitment to developing cutting-edge cancer therapies.
Neuroscience
The neuroscience division of AbbVie focuses on neurodegenerative and psychiatric disorders. Its notable products include:
- VRAYLAR (cariprazine): Used for the treatment of schizophrenia and bipolar disorder, demonstrating significant effects on mood stabilization and psychotic symptoms.
- Duopa (carbidopa/levodopa): A unique gel formulation developed for advanced Parkinsons disease that allows for continuous delivery of medication.
- ABBV-951: An investigational treatment aiming to improve outcomes for patients with Parkinsons disease, highlighting AbbVies innovative approach in neuroscience.
Virology
AbbVie has made substantial contributions in the field of virology, particularly in the treatment of viral hepatitis. Key products include:
- MAVIRET (glecaprevir/pibrentasvir): This combination therapy for hepatitis C boasts high cure rates and is significant in the realm of antiviral treatments.
- VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir/dasabuvir): Another hepatitis C treatment, VIEKIRA PAK is pivotal for patients who require effective antiviral agents.
Womens Health
AbbVie addresses the unique health needs of women through specific therapies, including:
- ELAGOLIX: Approved for managing endometriosis-related pain and also utilized for treating uterine fibroids, this treatment represents a strategic focus on womens health conditions.
- ABBV-181: In development for gender-specific conditions, reflecting AbbVie’s comprehensive approach to addressing womens health across a spectrum of needs.
Other Notable Products
1. Pain Management and Anesthesia
AbbVie’s contributions to pain and anesthesia include:
- DEPAKOTE (divalproex sodium): Indicated for epilepsy, bipolar disorder, and migraine prophylaxis, showcasing versatility in treatment options for neurological conditions.
- ULTANE (sevoflurane): An inhalation anesthetic agent utilized during surgeries, representing AbbVies expertise in anesthetic medications.
Infectious Diseases
AbbVie offers a selection of anti-infectives, such as:
- BIAxin (clarithromycin): Effective against a range of bacterial infections.
- OMNICEF (cefdinir): An oral antibiotic targeting specific bacterial infections, enhancing AbbVies portfolio in infectious diseases.
Metabolic Disease
AbbVie provides treatments for metabolic disorders, including:
- TRICOR (fenofibrate): Used to manage dyslipidemia, aiding in cardiovascular risk reduction.
- NIASPAN (niacin): Effective in managing cholesterol levels, underlining AbbVies commitment to chronic disease management.
Cardiovascular Drugs
AbbVie’s cardiovascular product offerings include:
- LISINOPRIL: A widely prescribed medication for hypertension.
- ATENOLOL: Another antihypertensive agent that helps manage blood pressure and cardiac conditions.
Research and Development Services
AbbVie emphasizes research and development as a cornerstone of its operations. Key R&D services encompass:
- Clinical Trials: Essential for evaluating the safety and efficacy of new compounds across various therapeutic areas.
- Collaborative Research: Engaging in partnerships with academic institutions and biotech companies to expedite innovative drug development and research efforts.
Summary
AbbVie Inc. has established itself as a leading global biopharmaceutical company with a diverse and extensive portfolio of pharmaceutical products across multiple therapeutic areas. Its strategic focus on immunology, oncology, neuroscience, virology, and womens health, combined with dedicated research and development initiatives, positions the company as an influential contributor to addressing significant health challenges worldwide. AbbVie’s commitment to advancing healthcare through innovation and effective treatments continues to be a significant aspect of its operations and mission.
Pharmaceutical Products Segment
1. Immunology
AbbVies immunology portfolio is headlined by HUMIRA (adalimumab), one of the worlds top-selling drugs, which has received approval for a variety of autoimmune diseases. This includes conditions such as:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Hidradenitis Suppurativa
In addition to HUMIRA, AbbVie has introduced newer agents into the market, including:
- RINVOQ (upadacitinib): An oral Janus kinase (JAK) inhibitor that treats rheumatoid arthritis and atopic dermatitis, emphasizing its effectiveness in managing moderate to severe conditions.
- ABBV-181: An investigational drug under development specifically targeting atopic dermatitis and other inflammatory diseases, showcasing AbbVies commitment to innovation within this therapeutic area.
Oncology
AbbVie has positioned itself as a critical player in oncology, with a focus on developing therapies for various cancers. Key products include:
- IMBRUVICA (ibrutinib): A Brutons tyrosine kinase (BTK) inhibitor that has gained approval for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), offering significant benefits in terms of progression-free survival.
- VENCLEXTA (venetoclax): An oral BCL-2 inhibitor, which is often utilized in combinations for treating CLL, further enhancing treatment efficacy.
- ABBV-927: Currently in clinical trials for various cancer types, this drug is indicative of AbbVies ongoing commitment to developing cutting-edge cancer therapies.
Neuroscience
The neuroscience division of AbbVie focuses on neurodegenerative and psychiatric disorders. Its notable products include:
- VRAYLAR (cariprazine): Used for the treatment of schizophrenia and bipolar disorder, demonstrating significant effects on mood stabilization and psychotic symptoms.
- Duopa (carbidopa/levodopa): A unique gel formulation developed for advanced Parkinsons disease that allows for continuous delivery of medication.
- ABBV-951: An investigational treatment aiming to improve outcomes for patients with Parkinsons disease, highlighting AbbVies innovative approach in neuroscience.
Virology
AbbVie has made substantial contributions in the field of virology, particularly in the treatment of viral hepatitis. Key products include:
- MAVIRET (glecaprevir/pibrentasvir): This combination therapy for hepatitis C boasts high cure rates and is significant in the realm of antiviral treatments.
- VIEKIRA PAK (ombitasvir/paritaprevir/ritonavir/dasabuvir): Another hepatitis C treatment, VIEKIRA PAK is pivotal for patients who require effective antiviral agents.
Womens Health
AbbVie addresses the unique health needs of women through specific therapies, including:
- ELAGOLIX: Approved for managing endometriosis-related pain and also utilized for treating uterine fibroids, this treatment represents a strategic focus on womens health conditions.
- ABBV-181: In development for gender-specific conditions, reflecting AbbVie’s comprehensive approach to addressing womens health across a spectrum of needs.
Other Notable Products
1. Pain Management and Anesthesia
AbbVie’s contributions to pain and anesthesia include:
- DEPAKOTE (divalproex sodium): Indicated for epilepsy, bipolar disorder, and migraine prophylaxis, showcasing versatility in treatment options for neurological conditions.
- ULTANE (sevoflurane): An inhalation anesthetic agent utilized during surgeries, representing AbbVies expertise in anesthetic medications.
Infectious Diseases
AbbVie offers a selection of anti-infectives, such as:
- BIAxin (clarithromycin): Effective against a range of bacterial infections.
- OMNICEF (cefdinir): An oral antibiotic targeting specific bacterial infections, enhancing AbbVies portfolio in infectious diseases.
Metabolic Disease
AbbVie provides treatments for metabolic disorders, including:
- TRICOR (fenofibrate): Used to manage dyslipidemia, aiding in cardiovascular risk reduction.
- NIASPAN (niacin): Effective in managing cholesterol levels, underlining AbbVies commitment to chronic disease management.
Cardiovascular Drugs
AbbVie’s cardiovascular product offerings include:
- LISINOPRIL: A widely prescribed medication for hypertension.
- ATENOLOL: Another antihypertensive agent that helps manage blood pressure and cardiac conditions.
Research and Development Services
AbbVie emphasizes research and development as a cornerstone of its operations. Key R&D services encompass:
- Clinical Trials: Essential for evaluating the safety and efficacy of new compounds across various therapeutic areas.
- Collaborative Research: Engaging in partnerships with academic institutions and biotech companies to expedite innovative drug development and research efforts.
Summary
AbbVie Inc. has established itself as a leading global biopharmaceutical company with a diverse and extensive portfolio of pharmaceutical products across multiple therapeutic areas. Its strategic focus on immunology, oncology, neuroscience, virology, and womens health, combined with dedicated research and development initiatives, positions the company as an influential contributor to addressing significant health challenges worldwide. AbbVie’s commitment to advancing healthcare through innovation and effective treatments continues to be a significant aspect of its operations and mission.